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Abstract
Anemia is associated with poor prognosis in patients hospitalized with acute decompensated heart 
failure (ADHF). Whether the impact of anemia differs by heart failure with preserved (HFpEF) or 
reduced (HFrEF) ejection fraction is uncertain. We examined hospital surveillance data captured 
by the Atherosclerosis Risk in Communities Study from January 1, 2005 – December 31, 2010. 
Diagnoses of ADHF were validated by standardized physician review of the medical record. 
Anemia was classified using WHO criteria (<12 g/dL for women, < 13 g/dL for men), and heart 
failure type was determined by the ejection fraction (<40% for HFrEF, ≥ 40% for HFpEF). 
Hospital length of stay and 1-year mortality outcomes were analyzed by multivariable regression, 
weighted to account for the sampling design, and adjusted for demographics and clinical 
covariates. Over 6 years, 15,461 (weighted) hospitalized events for ADHF (59% HFrEF) occurred 
in the ARIC catchment, based on 3,309 sampled events. Anemia was associated with a mortality 
hazard ratio of 2.1 (95% CI: 1.6 – 2.7) in patients classified with HFpEF, and 1.4 (95% CI: 1.1 – 
1.7) among those with HFrEF; p for interaction = 0.05. The mean increase in length of hospital 
stay associated with anemia was 3.5 days (95% CI: 3.4 – 3.6) for patients with HFpEF, compared 
with 1.8 days (95% CI: 1.7 – 1.9) for those with HFrEF; p for interaction <0.0001. In conclusion, 
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the incremental risks of death and lengthened hospital stay associated with anemia are more 
pronounced in ADHF patients classified with HFpEF than HFrEF.
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Introduction
Anemia is a common comorbidity of heart failure (HF), and has been associated with poor 
functional status1, longer hospitalizations2, re-hospitalizations3, and death4. In clinical trials, 
the benefit of anemia treatment to HF patients has been questionable5-7. However, most 
research has focused on HF with reduced ejection fraction (HFrEF), and there is some 
evidence to suggest the impact of anemia may differ by HF type8. This trend has not been 
consistently reported though9, 10, and few studies have examined outcomes in patients 
hospitalized with acute decompensated heart failure (ADHF). We investigated whether the 
mortality risk and length of hospital stay (LOS) associated with anemia would differ by HF 
type, by analyzing a population-based sample of ADHF hospitalizations captured by the 
Atherosclerosis Risk in Communities (ARIC) study.
Methods
Since 2005, the ARIC study has conducted population-based retrospective surveillance of 
hospitalized events in Forsyth County, North Carolina; Washington County, Maryland; 
Jackson, Mississippi; and 8 northwest suburbs of Minneapolis, Minnesota. Surveillance 
eligibility is restricted to residents 55 years of age or older, with a hospitalization spanning 
at least one day and, for the purposes of our analysis, a discharge date between January 1, 
2005 – December 31, 2010. Hospitalizations with any discharge codes for congestive HF, 
rheumatic heart disease, hypertensive heart disease, acute cor pulmonale, chronic pulmonary 
heart disease, cardiomyopathies, acute edema of lung, or dyspnea were randomly sampled, 
using pre-specified sampling fractions within strata of ARIC communities, ICD-9 code 
(428.x or all other eligible codes), age (55-74, 75-84, or ≥85), sex, and race (black or white).
Hospitalized medical records indicating signs or symptoms of HF were fully abstracted and 
reviewed by ARIC physicians, as previously described11. Using standardized criteria, 
hospitalizations were classified as definite ADHF, probable ADHF, stable chronic HF, not 
HF, or unclassifiable; based on diagnostic reports from the hospital record, physician notes, 
and discharge summaries. ADHF was differentiated from stable, chronic HF by evidence of 
new onset or worsening signs or symptoms.
Hemoglobin and serum creatinine were abstracted from the medical record, by recording the 
lowest and last values over the course of the hospitalization. To minimize potential 
confounding by hemodilution12, the last values were used to determine anemia and 
glomerular filtration rate. For the purposes of our analysis, anemia was defined by World 
Health Organization criteria (hemoglobin < 12 g/dL for women and < 13 g/dL for men). 
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Polycythemia was considered a hemoglobin value ≥ 17 g/dL. Glomerular filtration rate was 
estimated by the Chronic Kidney Disease Epidemiology Collaboration formula13.
HF type was determined by the abstracted ejection fraction, from either inpatient diagnostic 
tests, or when absent, pre-admission imaging studies. The majority of abstracted ejection 
fractions (71%) were in-hospital, and of these, 96% were based on transthoracic 
echocardiograms. Consistent with previous analyses of hospitalized ADHF and 
anemia8, 14-16, HFpEF was classified by a normal or mildly decreased systolic function 
(ejection fraction ≥ 40%) whereas HFrEF was considered an ejection fraction < 40%.
Length of stay (LOS) was calculated by subtracting the admission date from the discharge 
date, excluding transfers to and from another hospital. Mortality outcomes were ascertained 
for up to one year post-admission, by linking hospital records with death files.
Over six years, 6,291 hospitalizations were sampled and abstracted. Of these, 4,271 were 
classified as definite or probable ADHF. We omitted hospitalizations with no abstracted 
hemoglobin values (n = 33) or ejection fraction (n = 576), and patients transferred to or from 
another hospital (n=77). In addition, we excluded patients receiving dialysis (n = 337), as 
this represents a distinct subgroup of anemic HF, and patients identified with polycythemia 
(n = 19), due to the known U-shaped relation between hemoglobin and mortality risk17-19. 
After exclusions, 3,309 unweighted events remained in analysis, corresponding to 15,461 
weighted hospitalizations for definite (79%) or probable (21%) ADHF.
All analyses were performed using SAS 9.3 (SAS Institute; Cary, NC) and weighted by the 
inverse of the sampling probability. Proportions were compared using Rao-Scott χ2, and 
means were compared using analysis of variance. Correlations of hemoglobin with ejection 
fraction, age and GFR were assessed by Pearson regression. The crude incidence of death 
was examined by Kaplan-Meier regression. Adjusted mortality hazard ratios were examined 
using Cox regression, and associations with length of hospital stay were analyzed by linear 
regression. All multivariable regression models were adjusted for age, race, sex, and clinical 
covariates associated with anemia (glomerular filtration rate, smoking, systolic blood 
pressure, diastolic blood pressure, diabetes, coronary heart disease, beta blockers, and 
diuretics). Interactions were analyzed by entering the cross product of anemia and HF type, 
or the cross product of hemoglobin and HF type, into the fully adjusted models. Significance 
of interactions was assessed by Wald χ2 tests, using a threshold of α=0.10, due to reduced 
power to detect interaction20.
Results
All results are weighted to account for the sampling design, unless otherwise indicated. Of 
15,461 hospitalizations with verified ADHF, 6,414 (41%) were classified as HFpEF, and 
9,047 (59%) as HFrEF. The mean age at discharge was 76 years; approximately half (52%) 
were women, and nearly one third (29%) were black. The overall anemia prevalence was 
70%, and did not differ by HF type (p=0.4). In unadjusted analyses, hemoglobin was 
positively correlated with glomerular filtration rate (r = 0.21; p<0.0001) and negatively 
correlated with age (r = −0.11; p<0.0001) and ejection fraction (r = −.15; p<0.001).
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Patients classified with HFpEF were more often women (61% vs. 46%, p<0.0001), white 
(74% vs. 69%, p=0.003), and older (76 vs. 75 years, p=0.02) than those with HFrEF. 
Hypertension was more prevalent with HFpEF (86% vs. 83%, p=0.02), however myocardial 
infarction was less common (20% vs. 33%, p<0.0001). As shown in Table 1, gender-
specific mean hemoglobin levels were similar among patients with HFpEF and HFrEF. In 
univariate analyses, anemia was strongly associated with race, kidney function, blood 
pressure, smoking, and history of coronary heart disease for both HF types (p<0.05 for 
each). However, diabetes was associated with anemia only in HFpEF patients, while use of 
diuretics correlated with anemia only in those with HFrEF.
Overall, HFrEF was associated with greater mortality. In both types of HF, anemia was 
related to a higher incidence of death, and those with HFrEF and anemia fared worst 
(Figure 1). However, in relative analyses comparing outcomes of anemic with non-anemic 
HFpEF patients, and anemic with non-anemic HFrEF patients, the incremental risk of death 
was higher with HFpEF. After adjustments, anemia was associated with more than twice the 
risk of death in patients with HFpEF (HR = 2.1, 95% CI: 1.6 – 2.7), but only a 40% higher 
risk in those with HFrEF (HR = 1.4, 95% CI: 1.1 – 1.7); p for interaction = 0.05. As shown 
in Table 2, a slightly higher relative risk of death was also observed for HFpEF (HR = 1.2, 
95% CI: 1.1 – 1.3) compared with HFrEF (HR = 1.1, 95% CI: 1.0 – 1.2), when examining 
mortality risk per 1 g/dL decrement of hemoglobin.
On average, patients with HFpEF were hospitalized 1 day longer than those with HFrEF (8.0 
vs. 7.0 days, p=0.0009). Anemic patients had longer stays regardless of HF type, but those 
with HFpEF had the lengthiest time to discharge (8.9 vs. 7.5 days, p<0.0001). After 
adjustments, the absolute increase in mean LOS associated with anemia was 3.5 (3.3 – 3.6) 
days for patients with HFpEF, compared to 1.8 (1.7 – 1.9) days for those with HFrEF; p for 
interaction < 0.0001. The association remained robust when examining hemoglobin as a 
continuous measure. For each 1 g/dL decrement of hemoglobin, hospital stay was 
lengthened by 1.2 (1.1 – 1.2) days for patients with HFpEF, and 0.7 (0.6 – 0.7) days for 
those with HFrEF. When the analysis was restricted to patients discharged alive, the 
estimates were unchanged (data not shown).
Discussion
In this population-based sample of patients hospitalized with ADHF, anemia was associated 
with both greater mortality risk and longer hospital stays. We observed significantly stronger 
associations in patients with HFpEF, which remained robust when examining hemoglobin as 
a continuous measure.
Many studies have established anemia as risk factor for death in HF patients; however, 
comparisons of risk by HF type have been inconsistent for hospitalized ADHF. In a study 
from the National Heart Care Project involving 50,405 patients hospitalized with HF, 
slightly higher adjusted mortality risks were observed in patients with lower hematocrit 
levels, independent of left ventricular ejection fraction15. In contrast, the OPTIMIZE-HF 
registry, which prospectively followed 5,117 ADHF hospitalizations for mortality outcomes, 
reported significant interaction between HF type and hemoglobin level8. As with our study, 
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the overall worst mortality outcomes were noted in anemic patients with HFrEF. Although 
the OPTIMIZE-HF registry did not report relative risks within HFpEF and HFrEF groups, a 
crude analysis of the published data contrasting the lowest with highest hemoglobin 
quartiles yields a lower relative risk for patients with HFpEF (RR = 1.2) than HFrEF (RR = 
2.2). The lower mortality risk associated with anemia in HFpEF patients is contrary to our 
observations from the ARIC study. Consistent with our analysis, the adjusted hazard ratio of 
death associated with anemia was also greater with HFpEF (HR = 2.78) than HFrEF (HR = 
1.93) in a Scottish registry of 528 consecutive HF hospitalizations16.
We are aware of only two previous studies examining the association between anemia and 
hospital LOS in ADHF patients, and a single study which examined interaction by HF type. 
In an analysis of 8,569 patients hospitalized with HF, those with the lowest hemoglobin 
quartile were hospitalized an average 1.8 days longer than patients in the highest quartile, 
and incurred an additional $8,406 in mean charges2. In the OPTIMIZE-HF registry8, which 
reported crude LOS stratified by HF type, contrasts of the lowest with highest hemoglobin 
quartiles yield a similar increase in LOS for patients with HFpEF (1.30 days) and HFrEF 
(1.38 days), by our calculations. However, our analyses from the ARIC study revealed a 
different pattern. Contrasts of anemia with no anemia yielded a hospital stay lengthened by 
3.5 days for patients with HFpEF, and 1.8 days for those with HFrEF.
The anemia prevalence in our study, 70%, is consistent with previous reports of anemia and 
advanced HF. In ambulatory HF patients, anemia prevalence has been shown to increase 
with HF severity, from 9%, 19%, 53%, and 79% for NYHA class I-IV, respectively 21. 
However, national registries of ADHF hospitalizations with demographics similar to our 
study population have reported lower estimates of anemia prevalence. The ADHERE 
registry, based on 105,388 ADHF hospitalizations, reported an anemia prevalence of 
53% 22. Similarly, the reported anemia prevalence in the OPTIMIZE-HF registry was 
51% 8. The reason for the greater anemia prevalence in our study population is uncertain, 
but may be related to differing inclusion criteria. In the ARIC study, potential ADHF 
hospitalizations were identified for medical review using a broader range of ICD-9 codes 
than the OPTIMIZE-HF or ADHERE registries, and consequently, the ARIC study may 
have captured a higher prevalence of ADHF cases with comorbid conditions causing 
anemia.
We observed that anemic patients with HFpEF were less often treated with diuretics, and 
that anemia was only associated with diuretics in patients with HFrEF. This raises the 
possibility that hemodilutional anemia prevalence may differ by HF type. In a small study 
involving 46 ambulatory HF patients identified with anemia, examination of plasma volume 
by I-131 labeled albumin revealed 12% with HFpEF to be hemodilutional, compared to 41% 
with HFrEF23. To counter the possibility of hemodilution in our analysis, we defined anemia 
using the last hemoglobin value recorded in the hospital record. However, the specific time 
point of hemoglobin measurement was not abstracted, and hemodilution cannot be entirely 
ruled out. In the PROTECT trial, involving 1,969 patients hospitalized with HFrEF, 
hemoglobin levels were closely monitored by measurements on days 1-4 and day 7 of the 
hospitalization24. Short term improvement in hemoglobin levels was attributed to diuresis 
and abatement of hemodilution, and associated with better mortality outcomes. Though not 
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possible to confirm from the abstracted data, the disparity in relative outcomes that we 
observed among anemic HFpEF and HFrEF patients may relate to differing anemia 
etiologies and duration of anemia.
Our study has some limitations. Anemia therapies and red cell indices were not abstracted 
from the medical record, and we were unable to consider NYHA class as a potential 
modifier of associations between hemoglobin and mortality or LOS outcomes. We were also 
limited to hospitalizations with ejection fractions documented in the medical record. 
However, the ARIC study community surveillance provides a real-world glimpse into 
hospitalized ADHF, mitigating the selection bias by hospital catchment, medical insurance 
status, or trial inclusion criteria that may be encountered with other study designs. All 
hospitalizations for ADHF were validated by physician review of the medical record, 
minimizing misclassification of events, and sampled within pre-specified strata, to ensure an 
adequately representative study population.
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Unadjusted cumulative mortality one year following hospital admission date, stratified by 
heart failure type and anemia status
HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced 
ejection fraction; HR = hazard ratio of death associated with anemia
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Table 1
Weighted demographics and characteristics of hospitalized acute decompensated heart failure patients 
sampled by the ARIC Study community surveillance (2005 - 2010), stratified by heart failure type and anemia 
status
Characteristic HFpEF HFrEF
Anemia (n=4,566) No Anemia (n=1,848) Anemia (n=6,289) No Anemia (n=2,758)
No. (%) or Mean ± SEM No. (%) or Mean ± SEM
Female
* 2,675 (59%) 1,253 (68%) 2,844 (45%) 1,341 (49%)
Black
*† 1,297 (28%) 356 (19%) 1,826 (29%) 944 (34%)
Age (years)
† 77 ± 0.3 76 ± 0.4 76 ± 0.2 73 ± 0.3
Hemoglobin (g/dL)
    Women 10.3 ± 0.05 13.1 ± 0.06 10.4 ± 0.04 13.2 ± 0.06
    Men 10.6 ± 0.08 14.2 ± 0.07 10.9 ± 0.05 14.1 ± 0.05
Creatinine (mg/dL)
*† 1.6 ± 0.03 1.2 ± 0.02 1.6 ± 0.02 1.3 ± 0.02
GFR (mL/min/1.73 m2)
*† 48 ± 0.8 58 ± 0.9 48 ± 0.6 57 ± 0.8
BMI (kg/m2) 31 ± 0.3 31 ± 0.7 28 ± 0.2 29 ± 0.3
Systolic BP (mmHg)
*† 146 ± 1.1 148 ± 1.4 135 ± 0.9 142 ± 1.2
Diastolic BP (mmHg)
*† 75 ± 0.7 80 ± 0.8 75 ± 0.6 83 ± 0.8
Ejection Fraction (%)
† 54 ± 0.3 55 ± 0.4 34 ± 0.4 29 ± 0.5
Coronary Heart Disease
*† 2,078 (46%) 690 (37%) 3,189 (51%) 1,272 (46%)
Myocardial Infarction 975 (21%) 337 (18%) 2,109 (34%) 878 (32%)
Hypertension
* 4,414 (88%) 1,525 (83%) 5,240 (83%) 2,260 (82%)
Current Smoker
*† 487 (11%) 317 (17%) 799 (13%) 540 (20%)
COPD 1,406 (31%) 636 (34%) 2,215 (35%) 890 (32%)
Diabetes
* 2,350 (51%) 561 (30%) 2,953 (47%) 1,183 (43%)
ACE Inhibitors 1,727 (38%) 667 (36%) 2,555 (41%) 1,235 (45%)
Beta blockers
* 2,914 (64%) 1,050 (57%) 4,362 (69%) 1,790 (65%)
ARB 648 (14%) 333 (18%) 851 (14%) 360 (13%)
Diuretics
† 3,142 (68%) 1,208 (65%) 4,820 (77%) 1,991 (72%)
Statins 1,964 (43%) 745 (40%) 3,023 (48%) 1,187 (43%)
Mean stay (days)
*† 8.9 ± 0.3 5.6 ± 0.2 7.5 ± 0.2 5.7 ± 0.2
In-hospital Mortality
*† 348 (8%) 50 (3%) 517 (8%) 83 (3%)
28 day Mortality
*† 563 (12%) 122 (7%) 824 (13%) 250 (9%)
365 day Mortality
*† 1,652 (36%) 379 (21%) 2,724 (43%) 800 (29%)
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HFpEF = heart failure with preserved ejection fraction, HFrEF = heart failure with reduced ejection fraction, GFR = glomerular filtration rate, BMI 
= body mass index, BP = blood pressure, COPD = chronic obstructive pulmonary disease, ACE = angiotensin converting enzyme, ARB = 
angiotensin receptor blocker
*
significantly associated with anemia in patients with HFpEF (p<0.05)
†
significantly associated with anemia in patients with HFrEF (p<0.05)













Caughey et al. Page 11
Table 2
Adjusted risks associated with anemia status and hemoglobin (per 1 g/dL decrement) in patients hospitalized 
with acute decompensated heart failure, stratified by heart failure of preserved and reduced ejection fraction
Model
* Estimate P-value for interaction
†
1-Year mortality (Hazard ratio, 95% CI)
    Anemia vs. No Anemia 0.05
        HFpEF 2.1 (1.6 – 2.7)
        HFrEF 1.4 (1.1 – 1.7)
    Hemoglobin (per 1 g/dL decrement) 0.08
        HFpEF 1.2 (1.1 – 1.3)
        HFrEF 1.1 (1.0 – 1.2)
Length of stay increase (Days, 95% CI)
    Anemia vs. No Anemia < 0.0001
        HFpEF 3.5 (3.3 – 3.6)
        HFrEF 1.8 (1.7 – 1.9)
    Hemoglobin (per 1 g/dL decrement) < 0.0001
        HFpEF 1.2 (1.1 – 1.2)
        HFrEF 0.7 (0.6 – 0.7)
*
Models adjusted for age, sex, race, glomerular filtration rate, smoking, systolic blood pressure, diastolic blood pressure, diabetes, coronary heart 
disease, beta blockers use, and diuretics use
†
Interaction terms = (anemia × heart failure type) in anemia models and (hemoglobin × heart failure type) in hemoglobin models
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